# Rapid Micro Biosystems, Inc.: Form 10-Q for the period ended Sep 30, 2022

- Company: [Rapid Micro Biosystems, Inc.](/companies/rpid.md) (CIK 1380106)
- Form: 10-Q
- Filed: 2022-11-10
- Accepted by EDGAR: Nov 10, 2022, 16:44 ET
- Period: 2022-09-30
- Accession: 0001380106-22-000048
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1380106/000138010622000048/rmb-20220930.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1380106/000138010622000048/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2022-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2022-07-01 to 2022-09-30 | $4.7m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months, 2022-01-01 to 2022-09-30 | $12.8m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 3 months, 2022-07-01 to 2022-09-30 | $3.0m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2022-01-01 to 2022-09-30 | $9.5m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2022-07-01 to 2022-09-30 | −$16.9m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2022-01-01 to 2022-09-30 | −$46.0m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2022-07-01 to 2022-09-30 | $7.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2022-01-01 to 2022-09-30 | −$583.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2022-07-01 to 2022-09-30 | −$16.3m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2022-01-01 to 2022-09-30 | −$44.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2022-07-01 to 2022-09-30 | −$0.38 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2022-01-01 to 2022-09-30 | −$1.05 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2022-07-01 to 2022-09-30 | −$0.38 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2022-01-01 to 2022-09-30 | −$1.05 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2022-07-01 to 2022-09-30 | 42,517,992 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2022-01-01 to 2022-09-30 | 42,404,243 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2022-01-01 to 2022-09-30 | −$46.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2022-01-01 to 2022-09-30 | $5.9m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2022-09-30 | $25.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2022-09-30 | $144.6m | us-gaap:AssetsCurrent |
| Total assets | at 2022-09-30 | $201.9m | us-gaap:Assets |
| Current liabilities | at 2022-09-30 | $15.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2022-09-30 | $22.9m | us-gaap:Liabilities |
| Long-term debt | at 2022-09-30 | $0 | us-gaap:LongTermDebt |
| Shareholders' equity | at 2022-09-30 | $179.0m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 70,123 characters.

*The following discussion and analysis of our financial condition and results of operations should be read together with our consolidated condensed financial statements and the related notes appearing elsewhere in this Quarterly Report on Form 10-Q and our audited Consolidated Financial Statements and related notes thereto for the year ended December 31, 2021, included in the Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the SEC on March 24, 2022 (the “2021 Form 10-K”). Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the “Risk Factors” section of the 2021 Form 10-K, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.*

### Overview

We are an innovative life sciences technology company that enables the safe and efficient manufacture of pharmaceutical products through our rapid automated microbial quality control, or MQC, detection platform. We develop, manufacture, market and sell the Growth Direct system and related proprietary consumables, and value-added services to enable rapid MQC testing in the manufacture of biologics, cell and gene therapies, vaccines, sterile injectables, and other healthcare products. Our system delivers the power of industrial automation to bioprocessing and pharmaceutical manufacturing firms by modernizing and digitizing their MQC operations. Our Growth Direct platform, developed with over 15 years of active feedback from our customers, was purpose-built to meet the growing demands posed by the increasing scale, complexity, and regulatory scrutiny confronting global pharmaceutical manufacturing. Our Growth Direct platform comprises the Growth Direct system, optional laboratory information management system, or LIMS, connection software (which the majority of our customers purchase), proprietary consumables, and comprehensive field service, validation services and post-warranty service contracts. Once embedded and validated in our customers’ facilities, our Growth Direct platform provides for recurring revenues through ongoing sales of consumables and service contracts.

Our technology fully automates and digitizes the process of pharmaceutical MQC and is designed to enable our customers to perform this critical testing process more efficiently, accurately, and securely. Our Growth Direct platform accelerates time to results by several days, a 50% improvement over the traditional method, and reduces MQC testing to a simple two-step workflow, eliminating up to 85% of the manual steps of traditional MQC, generating significant time, operational, and cost savings for our customers. We seek to establish the Growth Direct as the trusted global standard in automated MQC by delivering the speed, accuracy, security, and data integrity compliance that our customers depend on to ensure patient safety and consistent drug supply.

Since inception, we have devoted a majority of our resources to designing, developing, and building our proprietary Growth Direct platform and associated products, launching our Growth Direct platform commercially, expanding our sales and marketing infrastructure to grow our sales, building a global customer support team to deliver our value-added services, investing in robust manufacturing and supply chain operations to serve our customers globally, and providing general and administrative support for these operations. To date, we have funded our operations primarily with proceeds from sales of preferred stock, proceeds from our IPO, borrowings under loan agreements and product and service sales as well as our cost-reimbursement contract with the U.S. Department of Health and Human Services Biomedical Advanced Research & Development Authority, or BARDA. All funding initially authorized under this contract was fully earned by the fourth quarter of 2021. We are now in the process of closing out our BARDA contract, which includes a true-up of actual reimbursable costs to those previously billed at provisional rates for each year of performance. Once the amount of each annual true-up is determined and approved by BARDA and they identify available funds to reimburse us for that amount, we expect to enter into a contract modification and invoice BARDA for the true-up amount, at which point we will recognize corresponding incremental non-commercial revenue in that amount. Based on the above and our current expectations for the timing of the true-up process, we do not currently anticipate recognizing any non-commercial revenue in the year ending December 31, 2022. However, we do anticipate recognizing the annual true-ups as non-commercial revenue as outlined above, which we currently expect to take place after 2022 over a period of up to several years.

On July 19, 2021, we closed an initial public offering of our Class A common stock, or the IPO, which resulted in the sale of 7,920,000 shares of our Class A common stock at a public offering price of $20.00 per share, before underwriting discounts. The IPO resulted in gross proceeds of $158.4 million and net proceeds of approximately $143.8 million after deducting underwriting discounts, commissions and estimated offering expenses payable by us. Additionally, on August 4, 2021, the underwriters exercised their overallotment option in part and purchased 1,086,604 shares of Class A common stock at the initial public offering price of $20.00 per share less discounts and commissions. The overallotment option exercise resulted in net proceeds of approximately $20.2 million. Immediately prior to the completion of the IPO, all of the outstanding shares of our Series A1, Series B1, Series C1 and Series D1 preferred stock converted into 24,200,920 shares of Class A common stock and all of the outstanding shares of our Series C2 and Series D2 converted into 6,903,379 shares of Class B common stock. As of September 30, 2022, no shares of our preferred stock remained outstanding.

On August 11, 2022, our board of directors approved an organizational restructuring plan, or the Restructuring Plan, to right-size our cost structure based on our lowered 2022 outlook. We will continue to invest in key growth initiatives including enhancing commercial execution and key product development programs that are expected to drive future revenue growth. The Restructuring Plan involves an approximately 20% reduction in our workforce, including employees, contractors and temporary employees, which is largely focused on non-commercial functions. We recorded a restructuring charge of approximately $1.1 million in the third quarter of 2022 primarily related to severance, employee benefits, outplacement and related costs under the Restructuring Plan. We expect the Restructuring Plan to result in approximately $8.0 - $9.0 million in annualized cost savings by the first quarter of 2023.

On August 12, 2022, we announced our board of directors' decision to reject an unsolicited, non-binding proposal we received from Kennedy Lewis Investment Management LLC to acquire all of our outstanding common stock for $5.00 per share in cash and to commence a process to review our strategic alternatives. No timetable has been established for the completion of this process, and we do not expect to disclose developments unless and until our board of directors has concluded that disclosure is appropriate or required.

Since our inception, we have incurred net losses in each year. We generated revenue of $4.7 million and $6.9 million for the three months ended September 30, 2022 and 2021, respectively, and incurred net losses of $16.3 million and $25.0 million for those same periods, respectively. We generated revenue of $12.8 million and $18.0 million for the nine months ended September 30, 2022 and 2021, respectively, and incurred net losses of $44.4 million and $58.9 million for those same periods, respectively. As of September 30, 2022, we had an accumulated deficit of $359.5 million. We expect to continue to incur net losses for the foreseeable future in connection with our ongoing activities, including:

- growing sales of our products in both the United States and international markets by further expanding our sales and marketing capabilities;
- scaling our manufacturing and supply chain processes and infrastructure to meet growing demand for our products;
- investing in research and development to develop new products and further enhance our existing products;
- protecting and building on our intellectual property portfolio; and
- attracting, hiring and retaining qualified personnel.

Until such time as we can generate revenue sufficient to achieve profitability, we expect to finance our operations through a combination of equity offerings and debt financings. If we are unable to raise capital or enter into such agreements as, and when, needed, we may have to significantly delay, scale back or discontinue our expansion plans including the further development and commercialization efforts of one or more of our products, or may be forced to reduce or terminate our operations.

We believe that our cash and cash equivalents and investments as of September 30, 2022 enable us to fund our operating expenses and capital expenditure requirements for at least the next twelve months. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. See “Liquidity and Capital Resources.”

### COVID-19 update

In response to the COVID-19 pandemic and various resulting government directives, we took proactive measures to protect the health and safety of our employees, customers, and partners, while maintaining our ability to supply and service our customers. We continue to monitor the implications of the ongoing COVID-19 pandemic on our business, as well as our customers’ and suppliers’ businesses.

As access to customer sites and in-person engagement continued to gradually improve in the three months ended September 30, 2022 (and through the date of this Quarterly Report on Form 10-Q), we continue to gain deeper insight into the challenges the pandemic created for our customers in advancing capital purchasing decisions and for us in accurately assessing the timing of sales opportunities.

While the disruption due to COVID-19, and its variants, is currently expected to be temporary, there is considerable uncertainty around its duration. Further disruptions in the future may impact our operating results. However, the related financial impact and duration of these disruptions cannot be reasonably estimated at this time.

### Effects of inflation and interest rates

The current inflationary environment and rising interest rates could have a negative impact on our results of operations, cash flows and overall financial condition. We may experience inflationary pressures on significant cost categories including labor, materials and freight. We continue to monitor the impact of inflation on these costs in order to minimize its effects through productivity improvements and cost reductions. There can be no assurance, however, that our operating results will not be affected by inflation in the future. In addition, inflation and increased interest rates may decrease demand for our Growth Direct systems, as our customers may face economic uncertainty as a result. A decrease in demand for our products or increases in our costs, as well as any steps we may take to mitigate changes, could impact our overall growth. However, the related financial impact cannot be reasonably estimated at this time.

### Factors affecting our performance

We believe that our financial performance has been, and in the foreseeable future will continue to be, primarily driven by multiple factors as described below, each of which presents growth opportunities for our business. These factors also pose important challenges that we must successfully address in order to sustain our growth and improve our results of operations. Our ability to successfully address these challenges is subject to various risks and uncertainties, including those described under the section titled “Risk Factors” to this Quarterly Report on Form 10-Q and other factors as set forth in Part I, Item 1A of the 2021 Form 10-K.

### New customer adoption of the Growth Direct platform

Our financial performance has largely been driven by, and a key factor to our future success will be, our ability to increase the global adoption of our Growth Direct platform in our key markets. We plan to drive global customer adoption through both direct and indirect sales and marketing organizations in North America, Europe, Asia and Australia.

We are investing in these organizations and expect to continue to do so in the future. As part of this effort, we increased our direct sales and marketing team by 9% during the nine months ended September 30, 2022. We expect the productivity of new resources in this organization to be fully realized over time.

### Expansion within our existing customer base

There is an opportunity to broaden adoption and increase utilization of our Growth Direct platform throughout our existing customers' organizations as these customers purchase more systems. These additional systems will allow our existing customers to convert more of their test volume at existing locations, to support multiple locations, to meet redundancy requirements, or to increase capacity. As of September 30, 2022, a majority of our customers have purchased Growth Direct systems for multiple sites, and approximately 60% of our customers have purchased multiple Growth Direct systems. Increased utilization amongst existing customers can also occur as customers advance through the Growth Direct platform adoption cycle from early validation of initial applications to validation and conversion of multiple applications on the Growth Direct platform.

### Innovating and launching new products on the Growth Direct platform

We believe the depth, scalability and robust capabilities of our Growth Direct platform allow us to address key opportunities and challenges facing MQC testing in the pharmaceutical industry. As an innovative leader in automated MQC testing, we intend to invest in further enhancements in our existing Growth Direct platform as well as end-to-end workflow solutions in our core market. We plan to further invest in research and development to support the expansion of our Growth Direct platform through development and launch of new applications to capture greater share of customer testing volume, new product formats to broaden our ability to serve different market segments and launch of new products and technologies to address adjacent segments of the overall MQC workflow. We plan to continue to hire employees with the necessary scientific and technical backgrounds to enhance our existing products and help us introduce new products to market. We expect to incur additional research and development expenses as a result. By expanding and continuously enhancing the Growth Direct platform, we believe we can drive incremental revenue from existing clients as well as broaden the appeal of our solutions to potential new customers.

### Expanding Growth Direct into adjacent end markets

We have identified several market expansion opportunities including deploying our existing Growth Direct platform into the personal care products market. We continuously seek to identify other market opportunities where our Growth Direct platform could enhance MQC testing. We could expand into these markets through our existing technologies, through adapting our existing technologies, or through developing new products to specifically address the unmet needs of these adjacent markets. We may drive our expansion into these markets by building commercial infrastructure to specifically target customers in those markets, or by partnering with other participants in those markets.

### Revenue mix

Our revenue is derived from sales of our Growth Direct systems, our LIMS connection software, proprietary consumables, services and our cost-reimbursement contract with BARDA. Growth Direct system revenue involves a capital selling process and tends to be somewhat concentrated within a small (but different) group of customers each year, it is subject to variability from quarter to quarter. As our base of validated Growth Direct systems continues to grow, we expect our recurring revenue (consumables and service contracts) to grow at a faster rate than our non-recurring revenues (Growth Direct systems, validation and other services), which we expect to drive variability and longer-term trends in our revenue mix.

Our non-commercial revenue has historically been generated from a long-term contract with BARDA. All funding awarded to-date under our contract with BARDA was fully earned by the fourth quarter of 2021. We are now in the process of closing out our BARDA contract, which includes a true-up of actual reimbursable costs to those previously billed at provisional rates for each year of performance. Once the amount of each annual true-up is determined and approved by BARDA and they identify available funds to reimburse us for that amount, we expect to enter into a contract modification and invoice BARDA for the true-up amount, at which point we will recognize corresponding incremental non-commercial revenue in that amount. Based on the above and our current expectations for the timing of the true-up process, we do not currently anticipate recognizing any non-commercial revenue in the year ending December 31, 2022. However, we do anticipate recognizing the annual true-ups as non-commercial revenue as outlined above, which we currently expect to take place after 2022 over a period of up to several years.

### Key business metrics

We regularly review the following key business metrics to evaluate our business, measure our performance, identify trends affecting our business, formulate financial projections and make strategic decisions. We believe that the following metrics are representative of our current business; however, we anticipate these may change or be substituted for additional or different metrics as our business grows and evolves.

*(dollars in thousands)*

| Systems placed: | Three Months Ended September 30, 2022 | 2021 | Change Amount% |  |
| --- | ---: | ---: | ---: | ---: |
| Systems placed in period | 3 | 10 | (7) | (70.0)% |
| Cumulative systems placed | 123 | 113 | 10 | 8.8% |
| Systems validated: |  |  |  |  |
| Systems validated in period | 4 | 5 | (1) | (20.0)% |
| Cumulative systems validated | 100 | 68 | 32 | 47.1% |
| Product and service revenue — total | $4,739 | $6,303 | $(1,564) | (24.8)% |
| Product and service revenue — recurring | $2,908 | $2,171 | $737 | 33.9% |

*(dollars in thousands)*

| Systems placed: | Nine Months Ended September 30, 2022 | 2021 | Change Amount% |  |
| --- | ---: | ---: | ---: | ---: |
| Systems placed in period | 7 | 26 | (19) | (73.1)% |
| Cumulative systems placed | 123 | 113 | 10 | 8.8% |
| Systems validated: |  |  |  |  |
| Systems validated in period | 16 | 17 | (1) | (5.9)% |
| Cumulative systems validated | 100 | 68 | 32 | 47.1% |
| Product and service revenue — total | $12,759 | $16,782 | $(4,023) | (24.0)% |
| Product and service revenue — recurring | $8,066 | $5,539 | $2,527 | 45.6% |

### Growth Direct system placements

We consider a Growth Direct system to be “placed” upon transfer of control of the system to the customer, at which point the revenue for that system is recognized. We regularly review the number of Growth Direct systems placed and cumulative Growth Direct system placements in each period as a leading indicator of our business performance. Our revenue has historically been driven by, and in the future will continue to be impacted by, the rate of Growth Direct system placements as a reflection of our success selling and delivering our products. We expect our Growth Direct system placements to continue to grow over time as we increase placements into our existing customers and markets and expand into new customers and markets.

The number of Growth Direct system placements and rate of growth varies from period-to-period due to factors including, but not limited to, Growth Direct system order volume and timing, and access to customer sites (including COVID-19 related restrictions and the timing of customer site construction activities). As a result, we expect to experience continued variability in our period-to-period number of Growth Direct system placements due to the aforementioned factors.

### Validated systems

We regularly review the number of Growth Direct systems validated and cumulative Growth Direct systems validated in each period as indicators of our business performance. Management focuses on validated Growth Direct systems as a leading indicator of likely future recurring revenue as well as a reflection of our success validating placed systems. We expect our validated Growth Direct systems to continue to grow over time as we increase our base of cumulative systems placed and then validate those systems. After a Growth Direct system is placed with a customer and installed, we work with the customer to validate the system, which typically takes anywhere from three to nine months.

Once a validation has been completed, we generally expect our customers to transition from their legacy manual method to our automated method and begin regular utilization of consumables over a period of up to three months.

The number of validated Growth Direct systems and rate of growth varies from period-to-period due to factors including, but not limited to, Growth Direct system order volume and timing, whether customers have previously validated Growth Direct systems within their site or network, access to customer sites (including as a result of COVID-19 related restrictions), customer site readiness and the time to install and validate each individual system. As a result, we expect to experience continued fluctuations in our period-to-period number of Growth Direct systems validated due to the aforementioned factors.

### Product and service revenue

We regularly assess trends relating to our combined product and service revenue as an indicator of our business performance. Product and service revenue represents all of our commercial revenue for the business. It excludes non-commercial revenue, which typically supports other business functions such as research and development and is by its nature subject to significant variability.

### Recurring revenue

We regularly assess trends relating to recurring revenue, which is the revenue from consumables and service contracts, based on our product offerings, our customer base and our understanding of how our customers use our products. Recurring revenue was 61.4% and 31.5% of our total revenue for the three months ended September 30, 2022 and 2021, respectively. Recurring revenue was 63.2% and 30.7% of our total revenue for the nine months ended September 30, 2022 and 2021, respectively. Our recurring revenue as a percentage of the total product and service revenue will generally vary based upon the number of Growth Direct systems placed and validated in the period, as well as other variables such as the volume of tests being conducted and the test application(s) being used on customers' Growth Direct systems. As our base of validated systems continues to grow, we expect our recurring revenue streams to grow at a faster rate that will ultimately result in our recurring revenue constituting the majority of our revenue over the longer term.

### Components of results of operations

### Revenue

We generate revenue from sales of our Growth Direct system including our LIMS connection software, consumables, validation services, service contracts and field service as well as our contractual arrangement with BARDA. We primarily sell our products and services through direct sales representatives. The arrangements are noncancellable and nonrefundable after ownership passes to the customer.

*(in thousands)*

*(in thousands)*

|  | Three Months Ended September 30, 2022 | Percentage of total revenue | Three Months Ended September 30, 2021 | Percentage of total revenue |
| --- | ---: | ---: | ---: | ---: |
| Product revenue | $3,209 | 67.7% | $4,824 | 69.9% |
| Service revenue | 1,530 | 32.3% | 1,479 | 21.4% |
| Non-commercial revenue | — | —% | 596 | 8.6% |
| Total revenue | $4,739 | 100.0% | $6,899 | 100.0% |

*(in thousands)*

*(in thousands)*

|  | Nine Months Ended September 30, 2022 | Percentage of total revenue | Nine Months Ended September 30, 2021 | Percentage of total revenue |
| --- | ---: | ---: | ---: | ---: |
| Product revenue | $8,212 | 64.4% | $12,630 | 70.1% |
| Service revenue | 4,547 | 35.6% | 4,152 | 23.0% |
| Non-commercial revenue | — | —% | 1,242 | 6.9% |
| Total revenue | $12,759 | 100.0% | $18,024 | 100.0% |

40

### Product revenue

We derive product revenue primarily from the sale of our Growth Direct systems and related consumables as well as our LIMS connection software, which the majority of our customers purchase. As of September 30, 2022, we had placed 123 Growth Direct systems to over thirty customers globally, including over half of the top twenty pharmaceutical companies as measured by revenue and approximately 30% of globally approved cell and gene therapies.

#### Growth Direct systems

Growth Direct system revenue is a non-recurring product revenue stream that we recognize as revenue upon transfer of control of the system to the customer. The Growth Direct system is fully functional for use by the customer upon delivery and, as such, transfer of control occurs at shipment or delivery depending on contractual terms.

We expect our Growth Direct system revenue to continue to grow over time as we increase system placements into our existing customers and markets and expand into new customers and markets.

#### Consumables

Our consumable revenue is a recurring product revenue stream composed of two proprietary consumables to capture test samples for analysis on the Growth Direct system, an Environmental Monitoring, or EM, consumable, and a Water/Bioburden consumable, or W/BB consumable. Both proprietary consumables support the growth-based compendial method for MQC testing mandated by global regulators and provide results that are comparable to traditional consumables. Our consumables are designed with features that enable automation on the Growth Direct system, with bar coding for tracking and data integrity, and physical characteristics for robotic handling, to support vision detection, and to prevent counterfeiting.

We expect consumable revenue to increase in future periods as our base of cumulative validated Growth Direct systems grows, those systems utilize our consumables on a recurring, ongoing basis and customers increase the rate of utilization of their systems.

#### LIMS Connection Software

Our LIMS connection software is a non-recurring product revenue stream. Although optional, the majority of our customers elect to purchase this software, which allows Growth Direct systems to export result reports and securely link to a customer’s two-way LIMS connection software to completely eliminate manual data entry and drive productivity.

### Service revenue

We derive service revenue from validation services, field service including installations, and service contracts sold to our customers. Revenue from validation services and field service are non-recurring service revenue streams, while revenue from service contracts is a recurring service revenue stream.

We offer our customers validation services (including related documentation) that enable them to replace their existing manual testing method and utilize their Growth Direct systems in compliance with relevant MQC regulations. Validation services are recognized as revenue over time as these services are provided to the customer.

We offer our customers service contracts that can be purchased after the expiration of the one-year assurance warranty that all of our customers receive with the purchase of a Growth Direct system. Under these contracts, they are entitled to receive phone support, emergency on-site maintenance support and two preventative maintenance visits per year. These service contracts generally have fixed fees and a term of one year. We recognize revenue from the sale of service contracts over time as these services are provided over the respective contract term.

We also offer our customers field service which consists of services provided by our field service engineers to install Growth Direct systems at customer sites. We recognize revenue from field service over time as these services are provided to the customer.

We expect service revenue to increase in future periods as the number of placed and validated Growth Direct systems grows. Specifically, we expect to generate increasing non-recurring revenue from validation services and field service for newly placed systems and increasing recurring revenue from service contracts for validated systems. While we expect service revenue growth to follow Growth Direct placements, such revenue is subject to variability based on other factors such as customer readiness and site construction.

### Non-commercial revenue

We have generated non-commercial revenue from long-term contracts with governmental agencies and third parties. To date, our non-commercial revenue has been derived from contracts with BARDA. All funding awarded to-date under our contract with BARDA was fully earned by the fourth quarter of 2021. We are now in the process of closing out our BARDA contract, which includes a true-up of actual reimbursable costs to those previously billed at provisional rates for each year of performance. Once the amount of each annual true-up is determined and approved by BARDA and they identify available funds to reimburse us for that amount, we expect to enter into a contract modification and invoice BARDA for the true-up amount, at which point we will recognize corresponding incremental non-commercial revenue in that amount. Based on the above and our current expectations for the timing of the true-up process, we do not currently anticipate recognizing any non-commercial revenue in the year ending December 31, 2022. However, we do anticipate recognizing the annual true-ups as non-commercial revenue as outlined above, which we currently expect to take place after 2022 over a period of up to several years.

### Costs and operating expenses

### Costs of revenue

Cost of product revenue primarily consists of costs for raw material parts and associated freight, shipping and handling costs, salaries and other personnel costs including stock-based compensation expense, contract manufacturer costs, scrap, warranty cost, inventory reserves, royalties, depreciation and amortization expense, allocated information technology and facility-related costs, overhead and other costs related to those sales recognized as product revenue in the period.

Cost of service revenue primarily consists of salaries and other personnel costs including stock-based compensation expense, travel costs, materials consumed when performing installations, validations and other services, allocated information technology and facility-related costs, costs associated with training, and other expenses related to service revenue recognized in the period.

Cost of non-commercial revenue primarily consisted of salaries and other personnel costs including stock-based compensation expense, consulting expense, materials, travel and other costs related to the revenue recognized as non-commercial revenue during the period. Our contract with BARDA was subject to the Federal Acquisition Regulation, or FAR, and is priced based on estimated or actual costs of producing goods or providing services. The FAR provides guidance on the types of costs that are allowable in establishing prices for goods or services provided under U.S. government contracts. All obligations under the BARDA contract were performed by the fourth quarter of 2021 and, as such, we do not currently anticipate recognizing any costs of non-commercial revenue in the year ending December 31, 2022.

### Research and development

Research and development expenses consist primarily of costs incurred for our research activities, product development, hardware and software engineering and consultant services and other costs associated with our technology Growth Direct platform and products, which include:

- employee-related expenses, including costs for salaries, bonuses and other personnel costs including stock-based compensation expense, for employees engaged in research and development functions;
- the cost of developing, maintaining and improving new and existing product designs;
- the cost of hardware and software engineering;
- research materials and supplies;
- external costs of outside consultants engaged to conduct research and development associated with our technology and products; and
- information technology and facilities expenses, which include direct and allocated expenses for rent, maintenance of facilities and insurance as well as related depreciation and amortization.

Our research and development costs are expensed as incurred. We believe that our continued investment in research and development is essential to our long-term competitive position, and we expect these expenses to increase in future periods.

### Sales and marketing

Sales and marketing expenses consist primarily of salaries, commissions, benefits and other personnel costs including stock-based compensation expense as well as costs relating to travel, consulting, public relations and allocated information technology and facility-related costs for our employees engaged in sales and marketing activities. We expect sales and marketing expenses to increase in future periods as the number of sales and marketing personnel grows and we continue to expand our geographic reach and capabilities, broaden our customer base and introduce new products.

### General and administrative

General and administrative expenses consist primarily of salaries, bonuses and other personnel costs including stock-based compensation expense for our finance, legal, human resources and general management employees, as well as professional fees for legal, patent, accounting, audit, investor relations, recruiting, consulting and other services. General and administrative expenses also include direct and allocated information technology and facility-related costs. General and administrative expenses are expected to increase in future periods as the number of administrative personnel grows to support increasing business size and complexity. We have also incurred incremental accounting, audit, legal, regulatory, compliance and director and officer insurance costs as well as investor relations expenses associated with operating as a public company. Additionally, we have incurred incremental expense associated with the unsolicited, non-binding proposal we received from Kennedy Lewis Investment Management LLC and our strategic alternatives review process. We anticipate that our general and administrative expenses will increase in the near future as we explore our strategic alternatives. These increases will likely include legal fees and fees to outside consultants, among other expenses.

### Other income (expense)

### Interest income (expense), net

Interest income (expense), net is comprised of interest cost associated with outstanding borrowings under our loan and security agreements, amortization of deferred financing costs and debt discounts associated with such arrangements. Income and accretion from investments is also included within this caption.

### Change in fair value of preferred stock warrant liability

In connection with the May 2020 term loan facility, we entered into with a lender, or the 2020 Term Loan, we issued 1,195,652 warrants to purchase shares of Series C1 Preferred Stock at an exercise price of $1.15 per share. These warrants were immediately exercisable and expire 10 years after the issuance date. We also have other outstanding warrants to purchase preferred stock issued in connection with previous financing arrangements.

We classified all of our warrants to purchase preferred stock as a liability on our consolidated balance sheets until our IPO because the warrants were freestanding financial instruments that may require us to transfer assets upon exercise. The liability associated with each of these warrants was initially recorded at fair value upon the issuance date and was subsequently remeasured to fair value at each reporting date. The resulting change in the fair value of the preferred stock warrant liability was recorded as a component of other income (expense) in our consolidated statements of operations. We continued to recognize changes in the fair value of this preferred stock warrant liability at each reporting period until the IPO when they qualified for equity classification.

In connection with the IPO, the preferred stock warrants were automatically converted to Class A common stock warrants. We determined the event resulted in equity classification of the Class A common stock warrants and derecognized the fair value of the preferred stock warrant liability as of the IPO date and reclassified to equity.

### Loss on extinguishment of debt

Loss on extinguishment of debt recognized in the three and nine months ended September 30, 2021, includes a loss from the extinguishment of the 2020 Term Loan. In addition, the loss on extinguishment of debt includes unamortized issuance costs, unamortized prepaid commitment fees, and early payment fees associated with the 2020 Term Loan repayment.

### Other income (expense), net

Other income primarily consists of other miscellaneous income and expense unrelated to our core operations.

### Income tax (benefit) expense

We generated significant taxable losses during the three and nine months ended September 30, 2022 and 2021 and, therefore, have not recorded any U.S. federal or state income tax expense during those periods. However, we did record an immaterial amount of foreign income tax expense during each of those periods. Additionally, as a result of a favorable outcome related to the tax examination for our Germany entity, we recorded an income tax benefit of $0.6 million for the nine months ended September 30, 2022.

### Results of operations

### Comparison of the three months ended September 30, 2022 and 2021

The following table summarizes our results of operations for the three months ended September 30, 2022 and 2021:

*(in thousands)*

| Revenue: | Three Months Ended September 30, 2022 | 2021 | Change Amount% |  |
| --- | ---: | ---: | ---: | ---: |
| Product revenue | $3,209 | $4,824 | $(1,615) | (33.5)% |
| Service revenue | 1,530 | 1,479 | 51 | 3.4% |
| Non-commercial revenue | — | 596 | (596) | (100.0)% |
| Total revenue | 4,739 | 6,899 | (2,160) | (31.3)% |
| Costs and operating expenses: |  |  |  |  |
| Cost of product revenue | 5,627 | 6,298 | (671) | (10.7)% |
| Cost of service revenue | 1,906 | 1,516 | 390 | 25.7% |
| Cost of non-commercial revenue | — | 396 | (396) | (100.0)% |
| Research and development | 2,973 | 2,441 | 532 | 21.8% |
| Sales and marketing | 3,930 | 3,063 | 867 | 28.3% |
| General and administrative | 7,189 | 5,308 | 1,881 | 35.4% |
| Total costs and operating expenses | 21,625 | 19,022 | 2,603 | 13.7% |
| Loss from operations | (16,886) | (12,123) | (4,763) | 39.3% |
| Other income (expense): |  |  |  |  |
| Interest income (expense), net | 575 | (761) | 1,336 | (175.6)% |
| Change in fair value of preferred stock warrant liability | — | (8,160) | 8,160 | (100.0)% |
| Loss on extinguishment of debt | — | (3,100) | 3,100 | (100.0)% |
| Other expense, net | (21) | (823) | 802 | (97.4)% |
| Total other income (expense), net | 554 | (12,844) | 13,398 | (104.3)% |
| Loss before income taxes | (16,332) | (24,967) | 8,635 | (34.6)% |
| Income tax (benefit) expense | 7 | 20 | (13) | (65.0)% |
| Net loss | $(16,339) | $(24,987) | $8,648 | (34.6)% |

### Revenue

Product revenue decreased by $1.6 million, or 33.5%. The decrease in product revenue was primarily the result of fewer Growth Direct system placements. The number of system placements and rate of growth varies from period-to-period due to factors including, but not limited to, the volume and timing of system orders. Higher shipments of consumables attributable to an increase in the cumulative number of validated Growth Direct systems had a favorable impact of $1.6 million on our revenue growth.

Service revenue increased by $0.1 million, or 3.4%. The increase in service revenue was primarily due to an increase in revenue from service contracts of $0.3 million related to an increase in the cumulative number of Growth Direct systems installed and on service contracts. This was partially offset by a $0.2 million decrease in validation and installation revenue due to lower system placements in the most recent three quarterly periods preceding the third quarter of 2022 as compared to the same periods in the prior year.

Non-commercial revenue was zero and $0.4 million for the three months ended September 30, 2022 and 2021, respectively. All funding under our contract with BARDA was fully earned by the fourth quarter of 2021 and, as such, we do not currently anticipate recognizing any non-commercial revenue in the year ending December 31, 2022.

During the three months ended September 30, 2021, restrictions on travel and access to customer sites related to COVID-19, and its variants, negatively impacted our ability to sell, ship, install and validate systems, as well as train customers in certain geographies. Although travel restrictions have gradually eased in many geographies in the three months ended September 30, 2022, the impact of previous travel restrictions negatively impacted our product and service revenue in the period. While we expect these disruptions may continue to impact our operating results, the related financial impact and duration of these disruptions cannot be reasonably estimated at this time.

### Costs and operating expenses

#### Costs of revenue

Cost of product revenue decreased by $0.7 million, or 10.7%. The reduction in cost of product revenue was driven by fewer Growth Direct systems placed in the period, partially offset by an increase in consumables costs due to higher unit volume sold. On a net basis, these factors accounted for $0.6 million of the decrease in cost of product revenue. In addition, efficiency-related reductions in per-unit net labor and overhead in consumables contributed to cost reductions of $0.3 million and $0.5 million, respectively. These decreases were partially offset by an increase of $0.3 million in warranty costs and $0.4 million in other product cost of goods sold.

Cost of service revenue increased by $0.4 million, or 25.7%. This increase was driven by an increase of $0.3 million due to higher compensation and benefit related costs associated with validation and field service employees as well as an increase in travel-related costs correlating with an increase in field service and validation activity to support our growing base of Growth Direct systems in the field. The remaining $0.1 million of the increase in cost of service revenue was attributable to an increase in other costs.

Cost of non-commercial revenue was zero for the three months ended September 30, 2022, compared to $0.4 million for the three months ended September 30, 2021. All funding under our BARDA contract was fully earned by the fourth quarter of 2021 and, as such, we do not currently anticipate recording any corresponding costs in the year ending December 31, 2022.

#### Research and development

*(dollars in thousands)*

|  | Three months ended September 30, 2022 | 2021 | Change Amount% |  |
| --- | ---: | ---: | ---: | ---: |
| Research and development | $2,973 | $2,441 | $532 | 21.8% |
| Percentage of total revenue | 62.7% | 35.4% |  |  |

Research and development expenses increased by $0.5 million, or 21.8%. This increase was primarily due to an increase of $0.2 million in employee-related costs due primarily to higher headcount and an increase in information technology and facility-related costs of $0.2 million to support growth including additional leased space to support our innovation initiatives. The remaining $0.1 million of the increase in research and development was attributable to an increase in other costs.

#### Sales and marketing

*(dollars in thousands)*

|  | Three months ended September 30, 2022 | 2021 | Change Amount% |  |
| --- | ---: | ---: | ---: | ---: |
| Sales and marketing | $3,930 | $3,063 | $867 | 28.3% |
| Percentage of total revenue | 82.9% | 44.4% |  |  |

Sales and marketing expenses increased by $0.9 million, or 28.3%. This increase was largely due to employee-related costs of $1.3 million primarily due to the restructuring expense recognized in conjunction with the August 2022 restructuring action as well as higher travel costs associated with our sales and marketing efforts in the third quarter of 2022. A $0.4 million increase in facilities and other costs also contributed to the increase. These increases were partially offset by a $0.8 million decrease attributable to non-recurring commercial consulting expenses and recruiting fees.

#### General and administrative

*(dollars in thousands)*

|  | Three months ended September 30, 2022 | 2021 | Change Amount% |  |
| --- | ---: | ---: | ---: | ---: |
| General and administrative | $7,189 | $5,308 | $1,881 | 35.4% |
| Percentage of total revenue | 151.7% | 76.9% |  |  |

General and administrative expenses increased by $1.9 million, or 35.4%. This increase was primarily driven by increased legal, investor relations and other costs of $1.2 million incurred related to the Kennedy Lewis unsolicited offer and strategic process announced on August 12, 2022. Also contributing to the increase was $0.5 million in employee-related compensation and benefits driven by one-time severance charges associated with the August 2022 restructuring action. The remaining increase of $0.2 million was the result of a net increase in other general and administrative expenses.

### Other income (expense)

#### Interest income (expense), net

Interest income (expense), net for the three months ended September 30, 2022 and 2021 was income of $0.6 million and expense of $0.8 million, respectively. The increase of $1.3 million, or 175.6%, was due to the repayment of our 2020 Term Loan in September 2021, as well as higher interest income resulting from higher interest rates in the third quarter of 2022.

#### Change in fair value of preferred stock warrant liability

The change in fair value of preferred stock warrant liability was zero for the three months ended September 30, 2022, compared to a loss of $8.2 million for the three months ended September 30, 2021. The loss in the prior year was due to an increase in the fair value of the underlying preferred stock immediately prior to conversion of common stock as a result of our IPO.

#### Loss on extinguishment of debt

Loss on extinguishment of debt was zero for the three months ended September 30, 2022, compared to a loss of $3.1 million for the three months ended September 30, 2021. The loss in the prior year was due to the repayment of our 2020 Term Loan in September 2021. We determined the loss on extinguishment of debt to be the difference between the reacquisition price of the debt and net carrying value of the extinguished debt.

#### Other expense

Other expense decreased by $0.8 million, or 97.4%. The decrease was due to non-recurring expense related to the exit fee, or the Exit Fee, in the amount of $0.8 million paid to a former lender following the IPO in the third quarter of 2021, as described in more detail in Note 16 to our consolidated financial statements included in the Annual Report on Form 10-K for the fiscal year ended December 31, 2021.

### Comparison of the nine months ended September 30, 2022 and 2021

The following table summarizes our results of operations for the nine months ended September 30, 2022 and 2021:

*(dollars in thousands)*

| Revenue: | Nine Months Ended September 30, 2022 | 2021 | Change Amount% |  |
| --- | ---: | ---: | ---: | ---: |
| Product revenue | $8,212 | $12,630 | $(4,418) | (35.0)% |
| Service revenue | 4,547 | 4,152 | 395 | 9.5% |
| Non-commercial revenue | — | 1,242 | (1,242) | (100.0)% |
| Total revenue | 12,759 | 18,024 | (5,265) | (29.2)% |
| **Costs and operating expenses:** |  |  |  |  |
| Cost of product revenue | 13,220 | 17,900 | (4,680) | (26.1)% |
| Cost of service revenue | 5,478 | 3,997 | 1,481 | 37.1% |
| Cost of non-commercial revenue | — | 1,282 | (1,282) | (100.0)% |
| Research and development | 9,463 | 6,926 | 2,537 | 36.6% |
| Sales and marketing | 10,870 | 8,460 | 2,410 | 28.5% |
| General and administrative | 19,687 | 12,135 | 7,552 | 62.2% |
| Total costs and operating expenses | 58,718 | 50,700 | 8,018 | 15.8% |
| Loss from operations | (45,959) | (32,676) | (13,283) | 40.7% |
| Other income (expense): |  |  |  |  |
| Interest income (expense), net | 947 | (2,603) | 3,550 | (136.4)% |
| Change in fair value of preferred stock warrant liability | — | (19,643) | 19,643 | (100.0)% |
| Loss on extinguishment of debt | — | (3,100) | 3,100 | (100.0)% |
| Other income (expense), net | 70 | (840) | 910 | (108.3)% |
| Total other income (expense), net | 1,017 | (26,186) | 27,203 | (103.9)% |
| Loss before income taxes | (44,942) | (58,862) | 13,920 | (23.6)% |
| Income tax (benefit) expense | (583) | 57 | (640) | (1,122.8)% |
| Net loss | $(44,359) | $(58,919) | $14,560 | (24.7)% |

### Revenue

Product revenue decreased by $4.4 million, or 35.0%. The decrease in product revenue was primarily attributable to fewer Growth Direct system placements resulting in $6.4 million lower product revenue, partially offset by $2.2 million of higher volume of consumable shipments related to the increase in the cumulative number of validated Growth Direct systems.

Service revenue increased by $0.4 million, or 9.5%. The increase in service revenue was primarily due to a $0.9 million increase related to service contracts, driven by an increase in the cumulative number of validated Growth Direct systems. This increase was partially offset by a $0.5 million decrease in validation and installation revenue related to lower system placements during the period as compared to the prior year.

Non-commercial revenue was zero and $1.2 million for the nine months ended September 30, 2022 and 2021, respectively. All funding under our BARDA contract was fully earned by the fourth quarter of 2021 and, as such, we do not currently anticipate recognizing any non-commercial revenue in the year ending December 31, 2022.

### Costs and operating expenses

#### Costs of revenue

Cost of product revenue decreased by $4.7 million or 26.1%. The reduction in cost of product revenue was driven by fewer systems placed in the period, partially offset by an increase in consumable costs due to higher unit volume sold. On a net basis, these factors accounted for a $2.2 million reduction in cost of product revenue. In addition, material cost savings, manufacturing efficiency, and other material related costs resulted in an additional $0.6 million reduction in cost of product revenue. The remainder of the decrease was attributable to a $1.1 million decrease due to manufacturing efficiencies in employee-related costs, including temporary labor, a $0.7 million decrease in net overhead expenses driven by production, as well as a $0.1 million reduction in other costs of product revenue.

Cost of service revenue increased by $1.5 million, or 37.1%. This increase was primarily due to $1.1 million of incremental spend on headcount-related costs and travel costs associated with additional validation and field service employees hired during 2021 and 2022 to support increased service activity. An increase in material costs of $0.4 million due to higher field service activity also contributed to the increase in cost of service revenue.

Cost of non-commercial revenue was zero for the nine months ended September 30, 2022, compared to $1.3 million for the nine months ended September 30, 2021. All funding under our BARDA contract was fully earned by the fourth quarter of 2021 and, as such, we do not currently anticipate recognizing any corresponding costs in the year ending December 31, 2022.

#### Research and development

*(dollars in thousands)*

|  | Nine Months Ended September 30, 2022 | 2021 | Change Amount% |  |
| --- | ---: | ---: | ---: | ---: |
| Research and development | $9,463 | $6,926 | $2,537 | 36.6% |
| Percentage of total revenue | 74.2% | 38.4% |  |  |

Research and development expenses increased by $2.5 million, or 36.6%. This increase was primarily due to an increase of employee-related costs due primarily to additional headcount as well as the timing of hiring and terminations. Higher information technology and facility-related charges to support growth including additional leased space to support our innovation initiatives at our Lowell, Massachusetts, facility also contributed to this increase.

#### Sales and marketing

*(dollars in thousands)*

|  | Nine Months Ended September 30, 2022 | 2021 | Change Amount% |  |
| --- | ---: | ---: | ---: | ---: |
| Sales and marketing | $10,870 | $8,460 | $2,410 | 28.5% |
| Percentage of total revenue | 85.2% | 46.9% |  |  |

Sales and marketing expenses increased by $2.4 million, or 28.5%. This increase was primarily due to an increase in employee-related costs of $3.1 million related to the expansion of our sales and marketing organizations, an increase of $0.7 million in other sales and marketing costs, and a $0.6 million restructuring charge recognized in the third quarter of 2022. This increase was partially offset by a $2.0 million decrease in non-recurring commercial consulting expenses which were incurred primarily related to our IPO.

#### General and administrative

*(dollars in thousands)*

|  | Nine Months Ended September 30, 2022 | 2021 | Change Amount% |  |
| --- | ---: | ---: | ---: | ---: |
| General and administrative | $19,687 | $12,135 | $7,552 | 62.2% |
| Percentage of total revenue | 154.3% | 67.3% |  |  |

General and administrative expenses increased by $7.6 million, or 62.2%. This increase was primarily due to a $3.2 million increase in employee-related costs driven primarily by timing of new headcount additions primarily in 2021, and one-time severance charges related to the August 2022 restructuring. Costs to operate as a public company including business insurance and compensation of the non-employee members of our board of directors resulted in $1.5 million in incremental expense. In addition, during the third quarter of 2022, the Company incurred increased legal, investor relations and other expenses of $1.4 million associated with the Kennedy Lewis unsolicited offer and efforts surrounding the strategic alternatives process announced on August 12, 2022. Also contributing to the cost increase was an increase in rent and depreciation expense of $1.2 million due to the addition of our Lexington, Massachusetts, facility during 2021, related depreciation of leasehold improvements and increased software costs due to a new enterprise resource planning (ERP) system implementation that was completed in late 2021. The remainder of the increase was attributable to a net increase of $0.3 million in other general and administrative expenses.

### Other income (expense)

#### Interest income (expense)

Interest income (expense) for the nine months ended September 30, 2022 and 2021 was income of $0.9 million and expense of $2.6 million, respectively. The increase of $3.6 million, or 136.4%, was due to the repayment of our 2020 Term Loan in September 2021, as well as higher interest income resulting from higher interest rates in the third quarter of 2022.

#### Change in fair value of preferred stock warrant liability

The change in fair value of preferred stock warrant liability was zero for the nine months ended September 30, 2022 compared to a loss of $19.6 million for the nine months ended September 30, 2021. The increase in value during the nine months ended September 30, 2021 was due primarily to an increase in the fair value of the underlying preferred stock, which is used to determine the value of preferred stock warrants, to reflect the IPO price. The increase in fair value was recorded upon the IPO prior to the conversion to Class A common stock warrants and reclassification to equity.

#### Loss on extinguishment of debt

Loss on extinguishment of debt was zero for the nine months ended September 30, 2022, compared to a loss of $3.1 million for the nine months ended September 30, 2021. The $3.1 million loss was incurred as a result of the repayment of the 2020 Term Loan. We determined the loss on extinguishment of debt to be the difference between the reacquisition price of the debt and net carrying value of the extinguished debt.

#### Other income (expense)

Other income (expense) increased by $0.9 million. The increase was due to a non-recurring expense related to the payment of a loan agreement Exit Fee in the third quarter of 2021 as described in Note 16 to our consolidated financial statements included in the Annual Report on Form 10-K for the fiscal year ended December 31, 2021.

### Income tax (benefit) expense

Income tax (benefit) expense was a benefit of $0.6 million for the nine months ended September 30, 2022 compared to an expense of less than $0.1 million for the nine months ended September 30, 2021. Both the benefit and the expense recorded related to our German subsidiary. During the nine months ended September 30, 2022, we adjusted an uncertain tax liability we had recorded for that subsidiary as a result of the favorable outcome of an examination for the tax years 2016 through 2018, resulting in the favorable income tax benefit in the period.

### Liquidity and capital resources

Since our inception, we have incurred significant operating losses. To date, we have funded our operations primarily through proceeds from sales of redeemable convertible preferred stock, borrowing under loan agreements, revenue from sales of our products and services as well as under our contracts with BARDA and proceeds from our IPO.

On August 11, 2022, our Board of Directors approved the Restructuring Plan to right-size our cost structure based on our lowered 2022 outlook. We will continue to invest in key growth initiatives including enhanced commercial capabilities and key product development programs that are expected to drive future revenue growth. We recorded a restructuring charge of approximately $1.1 million in the third quarter of 2022 primarily related to severance, employee benefits, outplacement and related costs under the Restructuring Plan. We made payments of $0.2 million during the three and nine months ended September 30, 2022 related to the Restructuring Plan and have $0.9 million recorded within accrued expenses as of September 30, 2022.

We believe that our cash, cash equivalents and short- and long-term investments will enable us to fund our operating expenses and capital expenditure requirements for at least twelve months following the date the condensed consolidated financial statements contained in this Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, were issued.

As of September 30, 2022, we had the following cash and investment-related assets on our condensed consolidated balance sheet (in thousands):

|  | September 30, 2022 |
| --- | ---: |
| Cash and cash equivalents | $25,832 |
| Short-term investments | 89,062 |
| Long-term investments | 35,214 |
| Restricted cash | 284 |
| Total | $150,392 |

#### Contractual obligations and commitments

In March 2022, we amended the lease for our office and manufacturing space in Lowell, Massachusetts or the Amendment. The Amendment increased the amount of facility space subject to the lease and extended the expiration of the lease from July 2026 to July 2029. The terms of the Amendment include options for a one-time, five-year extension of the lease and early termination of the lease in July 2026 (subject to an early termination fee), as well as a $0.3 million tenant improvement allowance. Monthly rent payments are fixed and future minimum lease payments under the lease (as amended) are $4.6 million.

### Cash flows

The following table summarizes our sources and uses of cash for each of the periods presented (in thousands):

|  | Nine Months Ended September 30, 2022 | 2021 |
| --- | ---: | ---: |
| Net cash used in operating activities | $(46,892) | $(42,077) |
| Net cash (used) provided by investing activities | (106,269) | 13,769 |
| Net cash provided by financing activities | 606 | 218,001 |
| Net (decrease) increase in cash and cash equivalents and restricted cash | $(152,555) | $189,693 |

51

### Operating activities

During the nine months ended September 30, 2022, operating activities used $46.9 million in cash, primarily as a result of our net loss of $44.4 million and net changes in our operating assets and liabilities of $8.2 million, partially offset by non-cash charges of $5.6 million. Net cash used by changes in our operating assets and liabilities for the nine months ended September 30, 2022 consisted of an increase in inventory of $5.5 million driven by an increase in finished goods and raw material inventory to support increased production volume and build safety stock in consumables, as well as a decrease in accounts payable of $0.3 million, a decrease in accrued expenses and other current liabilities of $2.8 million, and an increase in prepaid and other assets of $0.2 million. The cash used by operating assets and liabilities was partially offset by a decrease in accounts receivable of $0.3 million, and an increase in deferred revenue of $0.1 million.

During the nine months ended September 30, 2021, operating activities used $42.1 million in cash, primarily as a result of our net loss of $58.9 million and net changes in our operating assets and liabilities of $8.6 million, partially offset by non-cash charges of $25.4 million, which included a non-cash charge for the change in fair value of our preferred stock warrant liability of $19.6 million and a debt extinguishment loss of $3.1 million. Net cash used by changes in our operating assets and liabilities for the nine months ended September 30, 2021 consisted primarily of increases in inventory of $5.2 million driven by an increase in finished goods and raw material inventory to support increased production volume and to build safety stock, an increase in prepaid and other assets of $2.6 million driven by an increase in prepaid business insurance, as well as decreases in accounts payable of $2.2 million and deferred revenue of $0.5 million. The cash used by operating assets and liabilities was partially offset by an increase in accrued expenses and other liabilities of $2.6 million.

### Investing activities

During the nine months ended September 30, 2022, net cash used in investing activities was $106.3 million, due to purchases of investments of $155.3 million and purchases of property and equipment of $5.9 million, partially offset by maturities of investments of $55.0 million. The net cash used to purchase short- and long-term investments was the single largest contributor to our decrease in cash and cash equivalents and restricted cash for the nine months ended September 30, 2022.

During the nine months ended September 30, 2021, net cash provided by investing activities was $13.8 million, with cash provided by maturities of investments of $15.0 million partially offset by purchases of property and equipment of $1.3 million.

### Financing activities

During the nine months ended September 30, 2022, net cash provided by financing activities was $0.6 million, and was primarily related to the issuance of Class A common stock upon stock option exercises and in connection with purchases under our 2021 Employee Stock Purchase Plan.

During the nine months ended September 30, 2021, net cash provided by financing activities was $218.0 million, consisting of net proceeds from the IPO of $165.5 million, net proceeds of $79.7 million from the issuance of redeemable convertible preferred stock in March 2021 and $0.8 million in proceeds from the issuance of restricted common stock purchased by an employee and stock option exercises. These cash proceeds were partially offset by the repayment of the 2020 Term loan of $26.2 million and payment of debt extinguishment fees of $1.9 million in September 2021.

### Seasonality

Our revenues vary from quarter to quarter as a result of factors such as our customers’ budgetary cycles and extended summer vacation periods that can impact our ability to deliver products and provide onsite services to our customers during those periods. We expect this volatility to continue for the foreseeable future, which may cause fluctuations in our operating results and financial metrics. In addition, trends may vary in the future as our revenue mix shifts from non-recurring to recurring revenues.

### Critical accounting estimates

Our condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of our consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses, and the disclosure of contingent assets and liabilities in our consolidated financial statements. Our estimates are based on our historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.

Our significant accounting policies are described in more detail in Note 2 — Summary of Significant Accounting Policies to our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q. There have been no significant changes in our critical accounting policies and estimates as compared to the critical accounting policies and estimates disclosed in the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in the 2021 Form 10-K, other than as disclosed in Note 2.

### Recently issued accounting pronouncements

A description of recently issued accounting pronouncements that may potentially impact our financial position, results of operations or cash flows is disclosed in Note 2 — Summary of Significant Accounting Policies to our condensed consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q.

### Emerging growth company status

The Jumpstart Our Business Startups Act of 2012, or the JOBS Act, permits an “emerging growth company” such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, we will not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies, and our financial statements may not be comparable to other public companies that comply with new or revised accounting pronouncements as of public company effective dates. We may choose to early adopt any new or revised accounting standards whenever such early adoption is permitted for private companies.

We will cease to be an emerging growth company on the date that is the earliest of (i) the last day of the fiscal year in which we have total annual gross revenues of $1.235 billion or more, (ii) the last day of our fiscal year following the fifth anniversary of the date of the closing of the IPO, (iii) the date on which we have issued more than $1.0 billion in nonconvertible debt during the previous three years or (iv) the date on which we are deemed to be a large accelerated filer under the rules of the Securities and Exchange Commission.

Further, even after we no longer qualify as an emerging growth company, we may still qualify as a “smaller reporting company,” which would allow us to take advantage of many of the same exemptions from disclosure requirements, including reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We cannot predict if investors will find our common shares less attractive because we may rely on these exemptions. If some investors find our common shares less attractive as a result, there may be a less active trading market for our common shares and our share price may be more volatile.

## Market risk

As filed, 508 characters.

We are exposed to market risk in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. Our market risk exposure is primarily a result of fluctuations in interest rates and inflationary pressure. There has been no material change in our exposure to market risks from that discussed in Part II, Item 7A, “Quantitative and Qualitative Disclosures About Market Risk” of the 2021 Form 10-K.

## Controls and procedures

As filed, 1,580 characters.

### Limitations on effectiveness of controls and procedures

In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

### Evaluation of disclosure controls and procedures

Our management, with the participation of our principal executive officer and principal financial officer, evaluated, as of the end of the period covered by this Quarterly Report on Form 10-Q, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act). Based on that evaluation, our principal executive officer and principal financial officer concluded that, as of September 30, 2022, our disclosure controls and procedures were effective at the reasonable assurance level.

### Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended September 30, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 31,711 characters.

*Investing in our common stock involves a high degree of risk. Information regarding risk factors appears in Part I, Item 1A of our 2021 Form 10-K. Aside from the below, there have been no material changes from the risk factors previously disclosed in the 2021 Form 10-K.*

### Risks Related to Our Financial Position and Need for Capital

***Our operating results have fluctuated significantly in the past and will fluctuate significantly in the future, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations.***

Our quarterly and annual operating results have fluctuated significantly in the past and may fluctuate significantly in the future, which makes it difficult for us to predict our future operating results. These fluctuations may occur due to a variety of factors, many of which are outside of our control, including, but not limited to:

- our customers’ tendency to purchase our Growth Direct system, including multiple systems, in a single transaction, resulting in significant variations in sales of our systems over time;
- the level of demand for our platform and solutions, which may vary significantly;
- the length of time of the sales cycle for purchases of our systems;
- seasonality in our business due to our customers’ budgetary cycles and time off during the summer vacation;
- lead time needed for validation prior to our customers’ using and purchasing our consumables;
- changes in demand for our consumables;
- the timing and cost of, and level of investment in, technology development and commercialization activities, which may change from time to time;
- the start and completion of manufacturing runs;
- system repairs or replacements that may impact our customers’ confidence in us and our products and our reputation in the market;
- the relative reliability and robustness of our platform;
- the introduction of new products or product enhancements by us or others in our industry;
- expenditures that we may incur to acquire, develop or commercialize additional products and technologies;
- expenditures involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims;
- future accounting pronouncements or changes in our accounting policies;
- the ability of our sales organization to design and execute effective sales processes; and
- general market conditions and other factors, including factors, such as inflation, unrelated to our operating performance or the operating performance of our competitors.

The effect of one of the factors discussed above, or the cumulative effects of a combination of factors discussed above, could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance. We may continue to experience fluctuations in our operating results as a result of these factors.

***We may fail to meet our publicly announced guidance or other expectations about our business and future operating results, which could adversely affect our business, reputation and financial results and cause our stock price to decline.***

From time to time, we release earnings guidance in our quarterly and annual earnings conference calls, quarterly and annual earnings releases, or otherwise, regarding our future performance that represents our management’s estimates as of the date of release. This guidance includes forward-looking statements based on projections prepared by our management. Projections are based upon a number of assumptions and estimates that are based on information known when they are issued, and, while presented with numerical specificity, are inherently subject to significant business, economic, and competitive uncertainties and contingencies relating to our business, many of which are beyond our control and are based upon specific assumptions with respect to future business decisions, some of which will change. Some of those key assumptions include our customers’ demand for our Growth Direct systems, the length of the sales cycle for purchases of our systems, customer site readiness, the lead time needed for validation of our systems prior to customers using and purchasing our consumables, the timing and impact of the COVID-19 pandemic and the onset of variants, and broader macro-economic uncertainty. These assumptions are inherently difficult to predict. It can be expected that some or all of the assumptions underlying any guidance furnished by us will not materialize or will vary significantly from actual results. From time to time, we provide possible outcomes as high and low ranges, but these are not intended to imply that actual results could not fall outside of the suggested ranges.

Our actual business results may vary significantly from such guidance due to a number of factors, many of which are outside of our control, including our customers’ demand for our Growth Direct systems, the length of the sales cycle for purchases of our systems, customer site readiness and the lead time needed for validation of our systems prior to customers using and purchasing our consumables, as well as the impact of global economic uncertainty and financial market conditions, geopolitical events, such as the conflict in Ukraine, rising inflation, rising interest rates, and the COVID-19 pandemic, all of which could adversely affect our business and future operating results. There are no comparable recent events that provide insights on the probable effects of the COVID-19 pandemic and current macro-economic uncertainty, and, as a result, the ultimate impacts of the COVID-19 pandemic and/or the current macro-economic environment are highly uncertain and subject to change. Furthermore, if we make downward revisions of our previously announced guidance, or if our publicly announced guidance of future operating results fails to meet expectations of securities analysts, investors, or other interested parties, we may experience adverse effects on our business and reputation and the price of our common stock could decline.

In January 2022, we announced that our actual commercial revenue for the fiscal year ended December 31, 2021 was below our previous guidance, and in August 2022, we announced a downward revision in our commercial revenue guidance for the fiscal year ended December 31, 2022. Given the uncertainty surrounding our ability to design and execute more effective sales processes, generate and convert sufficient sales leads with new customers and place additional systems with existing customers, we may continue to fail to meet our publicly announced guidance in the future. Guidance is necessarily speculative in nature, and it can be expected that some or all of the assumptions underlying the guidance furnished by us will not materialize or will vary significantly from actual results. Accordingly, our guidance is only an estimate of what management believes is realizable as of the date of release. Actual results may vary from our guidance and the variations may be material. Investors are urged to exercise caution when using our guidance in making an investment decision regarding our common stock. Any failure to successfully implement our business strategy or the occurrence of any of the events or circumstances set forth in this Risk Factors section in this report could result in the actual operating results being different from our guidance, and the differences may be adverse and material.

### Risks Related to Our Business and Strategy

***The ongoing COVID-19 pandemic has impacted, and may continue to impact, our operations and may materially and adversely affect our business and financial results.***

Since late 2019, the COVID-19 pandemic has spread globally, including to the Boston, Massachusetts area, where our primary offices and manufacturing facility are located. The COVID-19 pandemic continues to evolve, and has led to the implementation of various responses, including government-imposed, shelter-in-place orders, quarantines, travel restrictions and other public health safety measures. In response to the spread of COVID-19, and its variants, and in accordance with direction from state and local government authorities, we have restricted access to our facilities mostly to personnel and third parties who must perform critical activities that must be completed on-site, limited the number of such personnel that can be present at our facilities at any one time, and requested that most of our personnel work remotely. In the event that government authorities modify current restrictions, our employees conducting development or manufacturing activities may not be able to access our manufacturing space, and our core activities may be significantly limited or curtailed, possibly for an extended period of time.

As a result of the ongoing COVID-19 pandemic, we have and may in the future experience severe disruptions, including:

- interruption of or delays in receiving products and supplies from the third parties we rely on to, among other things, manufacture components for our Growth Direct system and consumables, due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems, which may impair our ability to sell our products;
- limitations on our business operations by local, state, or the federal government that could impact our ability to sell our products;
- on-site visit limitations and prohibitions imposed by customers that could impact our ability to engage in pre-sales activities, such as in-person meetings and site visits, and to provide post-sale activities, such as installation and validation, training and service and support;
- delays in customers’ purchasing decisions and negotiations with existing and potential customers;
- business disruptions caused by workplace, laboratory and office closures and an increased reliance on employees working from home, travel limitations, cyber security and data accessibility, or communication or mass transit disruptions; and
- limitations on employee resources that would otherwise be focused on the conduct of our activities, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people.

Any of these factors could severely impact our development activities, business operations and sales, or delay necessary interactions with manufacturing sites and other important contractors and customers. For example, we experienced a disruption in receiving supplies from third parties and a decrease in installations as a result of the shutdown of our customers’ businesses. In addition, our sales and service processes have been significantly disrupted by our customers’ COVID-related restrictions and staffing shortages, which have impacted our customer site access and delayed systems placement timelines. These and other factors arising from the COVID-19 pandemic could worsen in countries that are already afflicted with COVID-19, and its variants, could continue to spread, or could return to countries where the pandemic has been partially contained, and could further adversely impact our ability to conduct our business generally and have a material adverse impact on our operations and financial condition and results.

The extent to which the outbreak may negatively impact our operations and results of operations or those of our third party manufacturers, suppliers, collaborators or customers will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate duration of the pandemic, subsequent waves of infection or variant strains, including the impact of the Delta and Omicron variants, the timing, availability, and effectiveness of vaccines as well as vaccination rates among the population, travel restrictions, and additional or modified government actions and private sector actions to contain the spread of COVID-19 or treat its impact, such as social distancing, quarantines, lock-downs or business closures.

***We have limited experience in marketing and sales, and if we are unable to improve the effectiveness of our marketing and sales organization to adequately expand our business with new and existing customers and address our customers’ needs, our business may be adversely affected.***

We have limited experience in marketing and selling our products and we currently rely on a small team to make direct sales in countries around the world. There are significant risks involved with relying on our own marketing and sales capabilities, including our ability to design and execute effective sales processes, generate and convert sufficient sales opportunities into new customers and place additional systems with existing customers. For example, in October 2021, we hired a new sales leader who implemented new sales processes which did not generate the system placements we anticipated. We are implementing improved sales processes, and there can be no assurance that those efforts will be successful.

Furthermore, in order to support our growth, we will need to increase our sales and marketing team. Competition for employees capable of selling expensive instruments within the drug manufacturing industry is intense. There are significant expenses and risks involved with having our own sales and marketing team, including our ability to hire, train, retain, and appropriately incentivize a sufficient number of qualified individuals, generate sufficient sales leads and provide our sales and marketing team with adequate access to customers who may want to purchase our products, effectively manage a geographically dispersed sales and marketing team, and other unforeseen costs and expenses. We may not be able to attract and retain personnel or be able to build an efficient and effective sales organization, which could negatively impact sales and market acceptance of our products and limit our revenue growth and potential profitability. In addition, the time and cost of establishing a specialized sales, marketing and service force for a particular product or service may be difficult to justify in light of the revenue generated or projected. Our sales processes may also be disrupted by our announced organizational restructuring plan and plans to explore strategic alternatives.

We may also choose to engage distributors for the sale of our products. We would exert limited control over these distributors, and if their sales and marketing efforts for our products are not successful, our business would be materially and adversely affected. We may not be successful in locating, qualifying and engaging distributors with local industry experience and knowledge, or we may not be able to enter into arrangements with them on favorable terms. Even if we are successful in identifying distributors, such distributors may engage in sales practices that violate local laws or our internal policies. Furthermore, sales practices utilized by any such distributors that are locally acceptable may not comply with sales practices standards required under U.S. laws that apply to us, which could create additional compliance risk.

Any of these issues could impair our ability to successfully place our Growth Direct systems and meet our revenue expectations. If we are unable to improve our sales processes and expand our marketing and sales organization, whether independently or with third parties, then our business, financial condition, results of operations and prospects will be materially adversely affected.

***Our organizational restructuring plan, including a reduction in workforce, announced in August 2022, may not result in anticipated savings, could result in total costs and expenses that are greater than expected and could disrupt our business.***

On August 12, 2022, we announced an approximately 20% reduction in our workforce, including employees, contractors and temporary employees, in connection with an organizational restructuring plan. We may not realize, in full or in part, the anticipated benefits and cost savings from our cost reduction efforts due to unforeseen difficulties, delays or unexpected costs. If we are unable to realize the expected operational efficiencies, improved commercial execution and cost savings from the restructuring, our operating results and financial condition could be adversely affected. If future results of operations lag our expectations, we may undertake additional workforce reductions or restructuring activities.

Our restructuring and any additional measures we might take to reduce costs could divert the attention of management, yield attrition beyond our intended reduction in workforce, reduce employee morale, or cause us to delay, limit, reduce or eliminate certain product development plans, each of which could have an adverse impact on our business, operating results and financial condition. This organizational restructuring plan may also reduce our existing customers’ confidence in us, disrupt our sales initiatives for new system placements, and negatively impact our customer service operations. Our failure to adequately address any of these issues could have a material adverse effect on our business, operating results and financial condition.

***The Growth Direct platform may contain undetected errors or defects and may not meet the expectations of our customers, which means our business, financial condition, results of operations and prospects could suffer.***

Our Growth Direct platform includes the Growth Direct system, proprietary consumables and our LIMS connection software. While we rigorously test our platform and its components, there could be undetected errors or defects. Disruptions or other performance problems with our platform or with the components that comprise our platform may adversely impact our customers’ manufacturing process, compliance workflow or business, harm our reputation and result in reduced revenue or increased costs associated with repairs or replacements. If that occurs, we may also incur significant costs, the attention of our key personnel could be diverted, or other significant customer relations problems may arise. We may also be subject to warranty claims or breach of contract for damages related to errors or defects in our products. Additionally, we may be subject to legal claims arising from any defects or errors in our platform, and in the systems, consumables and software that comprise our platform. In the past, we have repaired, and in exceptional cases, replaced Growth Direct systems under warranty. Our failure to adequately address any of foregoing risks related to errors or defects with our platform could have a material adverse effect on our business, operating results and financial condition.

Our success depends on, among other things, the market’s confidence that the Growth Direct platform is capable of substantially enhancing quality control in the conduct of manufacturing activities as compared to the traditional method of MQC testing and will enable more efficient or improved drug manufacturing. Pharmaceutical companies and contract manufacturing organizations, or CMOs, are likely to be particularly sensitive to defects and errors in the use of our platform, including if our platform fails to deliver meaningful improvements in MQC testing with results at least as good as the results generated using the traditional method of MQC testing. There can be no guarantee that our platform will meet the expectations of these companies or CMOs.

The complexity of our products and the amount of lead time required to deliver products to our customers have caused in the past, and may cause in the future, delays in releasing new products and workflows. In addition, we have experienced in the past, and may experience in the future, challenges with respect to the reliability of our systems. If there are delays in delivering our products to our customers, or if our products fail to perform as well as or better than traditional MQC testing or fail to generate reliable results for our customers, our revenue could be reduced or delayed, which could adversely affect our business, financial condition, results of operations and prospects.

These complexities also require that we train our customers to operate our Growth Direct platform, which is expensive and time consuming. Any misuse of our products, including as a result of inadequate training, could cause our products not to perform as expected or to fail to demonstrate the process advantages of our products. The training requirement may also deter some customers from utilizing our products. Any of these results could adversely affect our business, financial condition, results of operations and prospects.

***If we lose key management, cannot recruit qualified employees, directors, officers or other significant personnel or experience increases in our compensation costs, our business may be materially harmed.***

We are highly dependent on our management and directors, including our Chief Executive Officer, Robert Spignesi, among others. Due to the specialized knowledge each of our officers and key employees possesses with respect to our products and services and our operations, the loss of service of any of our officers or directors could delay or prevent the successful sales and expansion of our platform. We do not carry key person life insurance on our Chief Executive Officer or our other officers or directors. In general, the employment arrangements that we have with our executive officers do not prevent them from terminating their employment with us at any time.

In addition, our future success and growth will depend in part on the continued service of our directors, employees and management personnel and our ability to identify, hire and retain additional personnel. If we lose one or more of our executive officers or key employees, our ability to implement our business strategy successfully could be seriously harmed. Furthermore, replacing executive officers and key employees may be difficult or costly and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to develop, market and sell our products successfully. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or effectively incentivize these additional key personnel on acceptable terms given the competition among numerous technology companies for similar personnel. In addition, we rely on consultants and advisors to assist us in formulating our development and commercialization strategy. Our consultants and advisors may be engaged by entities other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us.

In August 2022, we implemented our organizational restructuring plan to reduce our operating expenses. In addition, we announced plans to explore strategic alternatives. These actions, and any future related actions or announcements, may make it increasingly difficult for us to hire and retain our executive officers, key employees, consultants and advisors. If we are unable to attract qualified personnel and retain our current employees, our ability to develop and sell our products could be limited and our business and customer relationships could be materially harmed.

### Risks Related to Our Common Stock

***Provisions in our restated certificate of incorporation and amended and restated bylaws and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.***

Provisions in our restated certificate of incorporation and our amended and restated bylaws may discourage, delay or prevent a merger, acquisition or other change in control of our company that stockholders may consider favorable, including transactions in which our stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our Class A common stock, thereby depressing the market price of our Class A common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions include those establishing:

- a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors;
- no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates;
- the exclusive right of our board of directors to elect a director to fill a vacancy created by the expansion of the board of directors or the resignation, death or removal of a director, which prevents stockholders from filling vacancies on our board of directors;
- the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquirer;
- the ability of our board of directors to alter our bylaws without obtaining stockholder approval;
- the required approval of the holders of at least two-thirds of the shares entitled to vote at an election of directors to adopt, amend or repeal our bylaws or repeal the provisions of our restated certificate of incorporation regarding the election and removal of directors;
- the required approval of the holders of at least two-thirds of the shares entitled to vote thereon to (i) effect a reorganization, recapitalization, share exchange, share classification, consolidation, conversion or merger, (ii) sell, lease, exchange, transfer or otherwise dispose of all or substantially all of our assets, or (iii) dissolve our company or revoke a dissolution of our company;
- a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders;
- the requirement that a special meeting of stockholders may be called only by the chairman of the board of directors, the chief executive officer, the president or the board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and
- advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders’ meeting, which may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer’s own slate of directors or otherwise attempting to obtain control of us.

In addition, on August 11, 2022, we adopted a stockholder rights agreement that could discourage potential acquisition proposals and could delay or prevent a change in control of the Company or a change in our management or board of directors, even in situations that may be considered beneficial by some of our shareholders.

Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the General Corporation Law of the State of Delaware, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.

***Our Rights Agreement could make it more difficult for a third party to acquire control of the Company, which could have a negative effect on the price of our common stock.***

On August 11, 2022, we adopted a stockholder rights agreement (the “Rights Agreement”) that could discourage potential acquisition proposals and could delay or prevent a change in control of the Company or a change in our management or board of directors, even in situations that may be considered beneficial by some of our stockholders. The Rights Agreement may substantially dilute the stock ownership of a person or group that attempts to acquire a large interest. These deterrents could also adversely affect the price of our Class A common stock. The Rights Agreement will automatically expire on the day after our 2023 Annual Meeting of Stockholders (the “2023 Annual Meeting”), unless approved by our stockholders at the 2023 Annual Meeting, in which case it will expire in one year, on August 11, 2023.

***Our process of exploring strategic alternatives may not result in a strategic transaction.***

On August 12, 2022, we announced our board of directors’ decision to reject an unsolicited, non-binding proposal we received from Kennedy Lewis Investment Management LLC to acquire all of our outstanding common stock for $5.00 per share in cash and the commencement of a process to review strategic alternatives. Our board of directors will review and consider a full range of possible alternatives, including, among other things, a possible sale, merger, strategic partnership or refinancing. We currently have no commitments or agreements with respect to any particular transaction, and there can be no assurance that our review of strategic alternatives will result in any strategic transaction. If our board of directors decides to proceed with a strategic transaction, it may not be at a price that our investors view as attractive relative to the value of our standalone strategic plan. Additionally, the closing of any such transaction would be dependent upon a number of factors that may be beyond our control, including, among other factors, market conditions, regulatory factors, industry trends, the interest of third parties in our business and the availability of financing to potential buyers on reasonable terms. If our board of directors decides not to proceed with a strategic transaction, this could have a negative effect on the market price and volatility of our common stock. In either case, we may incur substantial expenses associated with identifying and evaluating potential strategic transactions, the process may be time consuming and disruptive to our business, and we may be subject to costly and time-consuming litigation regarding our board of directors’ decision to proceed or not to proceed with a strategic transaction. Speculation and uncertainty regarding this process, including other actions taken by third parties, regardless of whether we are able to complete a strategic transaction, may also have a negative effect on:

- the market price and volatility of our Class A common stock;
- customer confidence in our business, products and services;
- our existing and potential future relationships with suppliers; and
- our ability to attract and retain key personnel who are necessary to the operation of the business, marketing and sales of our systems, and development of additional products.

Filed Nov 10, 2022.
Source: SEC EDGAR, the filing index for accession 0001380106-22-000048. Last ingested by Listed: Oct 24, 2026, 15:12 ET. No prices; not investment advice.
